Skip to main content

Yesterday, March 14, 2016, 82 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $5.92 to $72,390,000.00.

Highlighted Stocks Traded by Insiders:

Varonis Systems (VRNS) - FREE Research Report

Evergreen Iv L.P., who is 10% Owner at Varonis Systems, sold 10,000 shares at $18.22 on March 14, 2016. Following this transaction, the 10% Owner owned 3.5 million shares meaning that the stake was reduced by 0.29% with the 10,000-share transaction.

The shares most recently traded at $17.59, down $0.63, or 3.58% since the insider transaction. Historical insider transactions for Varonis Systems go as follows:

  • 4-Week # shares bought: 1,159
  • 4-Week # shares sold: 203,423
  • 12-Week # shares bought: 1,159
  • 12-Week # shares sold: 316,657
  • 24-Week # shares bought: 1,159
  • 24-Week # shares sold: 349,846

The average volume for Varonis Systems has been 165,300 shares per day over the past 30 days. Varonis Systems has a market cap of $475.1 million and is part of the technology sector and computer software & services industry. Shares are down 3.24% year-to-date as of the close of trading on Monday.

Varonis Systems, Inc. provides software platform for enterprises to analyze, secure, manage, and utilize their unstructured data. Currently, there are 3 analysts who rate Varonis Systems a buy, 1 analyst rates it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VRNS - FREE

TheStreet Quant Ratings

rates Varonis Systems as a

TheStreet Recommends

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity and generally disappointing historical performance in the stock itself. Get the full

Varonis Systems Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Cross Country Healthcare (CCRN) - FREE Research Report

Dircks Thomas C, who is Director at Cross Country Healthcare, bought 12,000 shares at $11.05 on March 14, 2016. Following this transaction, the Director owned 78,001 shares meaning that the stake was boosted by 18.18% with the 12,000-share transaction.

Grubbs William J, who is President and CEO at Cross Country Healthcare, bought 10,000 shares at $11.46 on March 14, 2016. Following this transaction, the President and CEO owned 238,395 shares meaning that the stake was boosted by 4.38% with the 10,000-share transaction.

Burns William J., who is Chief Financial Officer at Cross Country Healthcare, bought 2,600 shares at $11.05 on March 14, 2016. Following this transaction, the Chief Financial Officer owned 79,432 shares meaning that the stake was boosted by 3.38% with the 2,600-share transaction.

The shares most recently traded at $10.60, down $0.45, or 4.25% since the insider transaction. Historical insider transactions for Cross Country Healthcare go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 40,000
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 40,000
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 43,000

The average volume for Cross Country Healthcare has been 480,400 shares per day over the past 30 days. Cross Country Healthcare has a market cap of $373.3 million and is part of the services sector and diversified services industry. Shares are down 32.76% year-to-date as of the close of trading on Monday.

Cross Country Healthcare, Inc. provides healthcare staffing and workforce solutions in the United States. The company operates through three segments: Nurse and Allied Staffing, Physician Staffing, and Other Human Capital Management Services. The company has a P/E ratio of 81.9. Currently, there are 4 analysts who rate Cross Country Healthcare a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on CCRN - FREE

TheStreet Quant Ratings

rates Cross Country Healthcare as a

hold

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including a decline in the stock price during the past year and poor profit margins. Get the full

Cross Country Healthcare Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Northrop Grumman (NOC) - FREE Research Report

Warden Kathy J, who is Corp VP & Pres Mission Syst at Northrop Grumman, sold 4,366 shares at $189.00 on March 14, 2016. Following this transaction, the Corp VP & Pres Mission Syst owned 65,042 shares meaning that the stake was reduced by 6.29% with the 4,366-share transaction.

The shares most recently traded at $191.33, up $2.33, or 1.22% since the insider transaction. Historical insider transactions for Northrop Grumman go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 49,106
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 49,106
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 54,950

The average volume for Northrop Grumman has been 1.3 million shares per day over the past 30 days. Northrop Grumman has a market cap of $34.4 billion and is part of the industrial goods sector and aerospace/defense industry. Shares are down 0.13% year-to-date as of the close of trading on Monday.

Northrop Grumman Corporation, a security company, provides systems, products, and solutions in aerospace, electronics, information systems, and technical service areas to government and commercial customers worldwide. The stock currently has a dividend yield of 1.69%. The company has a P/E ratio of 18.3. Currently, there are 6 analysts who rate Northrop Grumman a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NOC - FREE

TheStreet Quant Ratings

rates Northrop Grumman as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, good cash flow from operations, notable return on equity, reasonable valuation levels and growth in earnings per share. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Northrop Grumman Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.